Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study).
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: [²¹²Pb]Pb-ADVC001
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- AdvanCell Isotopes Pty Limited
- Target Recruit Count
- 100
- Registration Number
- NCT05720130
- Locations
- 🇦🇺
Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Princess Alexandra Hospital, Brisbane, Queensland, Australia
News
Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceutical Research with AbYlink™ Technology
Swiss-based Debiopharm and French CRO Oncodesign Services have established a license agreement for AbYlink™, a regio-selective bioconjugation technology designed for therapeutic and non-invasive diagnostic applications.
Lilly Licenses Sangamo's Blood-Brain Barrier Capsid Technology in $1.4B CNS Deal
Eli Lilly has secured rights to Sangamo Therapeutics' STAC-BBB capsid technology for $18 million upfront, with potential milestone payments reaching $1.4 billion plus tiered royalties.
AdvanCell Secures $112M in Oversubscribed Series C to Advance Radiopharmaceutical Cancer Therapies
• AdvanCell, a clinical-stage radiopharmaceutical company, has successfully raised $112 million in an oversubscribed Series C financing round co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis. • The company is currently conducting a Phase I/II dose escalation trial of ADVC001, a Pb-212-based Targeted Alpha Therapy for metastatic prostate cancer, with patients being enrolled in the highest dose cohort. • Since its founding in 2019, AdvanCell has grown to 60 team members with a 40,000-square-foot manufacturing facility and will use the new funding to expand manufacturing capacity and accelerate clinical development of its radiopharmaceutical pipeline.